Price movement over the last 24 hours
ADMA Biologics Inc vs Kingsoft Cloud Holdings Limited — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while Kingsoft Cloud Holdings Limited trades at $10.62 (market cap $2.80B). The key difference: Kingsoft Cloud Holdings Limited is the larger of the two by market cap. Which is the better fit depends on your goals.
| ADMA | KC | |
|---|---|---|
Market Cap | $2.13B | $2.80B |
Sector | Health | Technology |
52-Week High | $20.38 | $18.21 |
52-Week Low | $7.60 | $8.58 |
Enterprise Value | $2.20B | $3.11B |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Kingsoft Cloud (KC) trades at $9.13 with a slight 0.33% daily gain, showing technical bearish signals despite recent earnings beats. The company reported $9.56B revenue for 2025 but continues to post net losses (-$936M), though AI-driven cloud demand is accelerating growth. Analyst sentiment remains positive with 70% buy ratings, while technical indicators show mixed signals with RSI levels suggesting potential oversold conditions.
KC presents a growth story fueled by AI cloud services expansion, but profitability challenges and negative margins create investor uncertainty. The stock's appeal hinges on management's ability to convert revenue growth into sustainable profits amid heavy infrastructure investments. Near-term catalysts include Q2 2026 earnings and margin improvement progress.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Kingsoft Cloud is a leading independent cloud service provider in China. It offers a comprehensive suite of cloud products and solutions tailored for industries like gaming, video streaming, and financial services.
Read more on KC →